Incyte and Edison Scientific announced a new strategic collaboration to advance pharmaceutical research and development. Incyte will officially employ the Kosmos AI Platform for its ongoing discovery and development work. The collaborative technology will be embedded directly across the entire Incyte lifecycle. This integration enables continuous learning from deep translational and clinical data. Consequently, the team can access real-time evidence synthesis and predictive models of therapeutic performance. The initial deployment focuses heavily on target discovery and target validation. Furthermore, scientists will use the platform for high-impact use cases in translational biology. Embedding these artificial intelligence capabilities within existing research workflows supports more efficient exploration. The specialized software evaluates experimental, clinical, and biomarker data. Over time, the platform has clear potential to expand across the broader R&D organization.
Transforming Research Data into Compounding Assets
The collaborative partners will actively measure the exact impact on decision quality. They will also track long-term pipeline productivity as the technology evolves. This business agreement establishes a brand new model for the biopharma industry. Under this setup, proprietary corporate data becomes a valuable compounding asset. The stored data trains advanced machine learning models that continuously improve over time.
“Our vision is for our data to become a learning system that enhances every decision,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development at Incyte. “This partnership aims to maximize our data’s value by integrating AI to guide experimental design and improve the quality and consistency of scientific and development decisions. Our goal is not just faster development, but better outcomes across our programs.”
This framework systematically enhances future experimental and clinical outcomes. The system generates a distinct feedback loop by interpreting complex scientific results.
“By using systems that learn from our experimental and clinical data, we can enhance result interpretation, creating a feedback loop that boosts both speed and quality in future programs,” added Patrick Mayes, Ph.D., Executive Vice President and Chief Scientific Officer at Incyte. Edison Scientific originally spun out of the nonprofit research lab FutureHouse in 2025. The scientist-led company secured $70M from Spark Capital, Triatomic Capital, and additional investors.
“Most AI efforts in pharma treat data as something to analyze,” said Sam Rodriques, Ph.D., Chief Executive Officer of Edison Scientific. “What we are building treats data as something to learn from continuously. The result is a system that compounds, where every experiment, every clinical readout, and every decision improves the underlying models. That is how companies, like Incyte, will turn their data into a sustainable advantage over their competitors.”
Incyte continues to focus on redefining possibilities within biopharmaceutical innovation. The global company holds established portfolios across Hematology, Oncology, and Inflammation and Autoimmunity franchises. The Kosmos AI Platform will support critical decisions to bring these next-generation medicines to market much faster.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
